HPV infection and number of lifetime sexual partners are strong predictors for ‘natural’ regression of CIN 2 and 3

por Chan, J K, Monk, B J, Brewer, C, Keefe, K A, Osann, K, McMeekin, S, Rose, G S, Youssef, M, Wilczynski, S P, Meyskens, F L, Berman, M L
Publicado 2003

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-...

por Poveda, A., Vergote, I., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Kaye, S. B., Colombo, N., Lebedinsky, C., Parekh, T., Gómez, J., Park, Y. C., Alfaro, V., Monk, B. J.
Publicado 2011

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

por Kaye, S. B., Colombo, N., Monk, B. J., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Vergote, I., Lebedinsky, C., Parekh, T., Santabárbara, P., Park, Y. C., Nieto, A., Poveda, A.
Publicado 2011

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ov...

por Monk, B. J., Brady, M. F., Aghajanian, C., Lankes, H. A., Rizack, T., Leach, J., Fowler, J. M., Higgins, R., Hanjani, P., Morgan, M., Edwards, R., Bradley, W., Kolevska, T., Foukas, P., Swisher, E. M., Anderson, K. S., Gottardo, R., Bryan, J. K., Newkirk, M., Manjarrez, K. L., Mannel, R. S., Hershberg, R. M., Coukos, G.
Publicado 2017